Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016826
Chunk: 21

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 21
---
5 was 61,952,308,922 Ordinary Shares, with each Ordinary Share having a nominal value of £0.000001
per share. Each issued Ordinary Share is fully paid. We currently have 1,000,001 A deferred shares, 4,063,321,418 B deferred shares,
126,547,389,518 C deferred shares, and 2,482,747,137,178 D deferred shares.

There is no limit to
the number of Ordinary Shares that we are authorized to issue, as the concept of authorized capital is no longer applicable under the
provisions of the Companies Act. There are no conversion rights, redemption provisions or sinking fund provisions relating to any Ordinary
Shares.

We are not permitted
under English law to hold our own Ordinary Shares unless they are repurchased by us and held in treasury. We do not currently hold any
of our own Ordinary Shares.

History of Share Capital

Since January 1, 2022,
our issued share capital has changed as provided below.

On March 22, 2022, we issued
one Ordinary Share upon the exercise of one warrant issued in February 2019 to a certain institutional investor at an exercise price of
£200 per share.

On May 3, 2022, we issued
1,250 Ordinary Shares to be purchased under our Share Incentive Plan at £0.02 per share to the trust of our Share Incentive Plan.

On August 3, 2022, we issued
warrants to purchase 16,666 Ordinary Shares to a certain institutional investor at an exercise price of £2.70 per share.

On September 26, 2022, we
effected a ratio change to the Depositary Shares, pursuant to which the ratio of Ordinary Shares to Depositary Shares was changed such
that one Depositary Share represented 25 Ordinary Shares. Our Ordinary Shares were not affected by this change and no fractional Depositary
Shares were issued.

On December 16, 2022,
we sold to an institutional investor 492,400 Ordinary Shares represented by 4 Depositary Shares in a registered direct offering at $80,000.00
per Depositary Share, resulting in gross proceeds of approximately $0.4 million.

On February 15, 2023,
we completed the closing of a private placement, or the February Private Placement, pursuant to which we sold to certain institutional
investors (1) 3,250,000 Ordinary Shares represented by